ALPINE GROUP PARTNERS, LLC. for EMERGENT BIOSOLUTIONS
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY26 Opioid crisis legislation, naloxone access and awareness State opioid response (SOR) Grant funding FY26 Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY26 Tribal Opioid Response Grant funding for FY26 NDAA for Fiscal Year 2025 and Fiscal Year 2026 - provisions related to biological and chemical defense and access to naloxone H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025 H.R. 2483, SUPPORT for Patients and Communities Reauthorization Act of 2025 H.R. 5252, HOPE Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| KEENAN AUSTIN REED | — |
| ERIN MENDELSOHN | LD, Rep. Anna Eshoo; Congressional Liaison - FDA |
| HANNAH SCHMIDT | Professional Staff, House Small Business Cmte |
| SHAYNE WOODS | — |
Aviation/Airlines/Airports AVI
Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY26 Opioid crisis legislation, naloxone access and awareness State opioid response (SOR) Grant funding FY26 Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY26 Tribal Opioid Response Grant funding for FY26 NDAA for Fiscal Year 2025 and Fiscal Year 2026 - provisions related to biological and chemical defense and access to naloxone H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025 H.R. 2483, SUPPORT for Patients and Communities Reauthorization Act of 2025 H.R. 5252, HOPE Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| KEENAN AUSTIN REED | — |
| ERIN MENDELSOHN | LD, Rep. Anna Eshoo; Congressional Liaison - FDA |
| HANNAH SCHMIDT | Professional Staff, House Small Business Cmte |
| SHAYNE WOODS | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.